Gel caps are soft gelatin capsules that enclose a liquid or oil-based drug inside a flexible gelatin shell. This packaging is ideal for medicines that are oil-based, because the soft capsule provides a tight seal and smooth, easy swallowing. The statement about a hard-shell capsule containing a gel material describes a different form; hard capsules are two-piece shells usually filled with dry powders or pellets, not liquids. A gel cap is not a dry powder inhalation, nor is it a syrup in a bottle, so those descriptions don’t fit.

The main idea here is that a control group provides a baseline for comparison in a trial. This group helps us see what happens without the experimental intervention, or with a neutral treatment like a placebo, so we can attribute any differences in outcomes to the intervention itself rather than to chance or other factors. Using a placebo (or standard care, when appropriate) helps blind participants and researchers, reducing bias and ensuring that observed effects are due to the treatment being tested. That makes the best choice the one that frames the control as the standard by which observations are evaluated, often with a placebo. It acknowledges the essential role of comparison and the common method of using a placebo to minimize bias. The group that receives the experimental drug describes the treatment group, not the control. And while a no-treatment control is possible in some trials, it isn’t universal or as informative as a placebo-based or standard-care control, which is why the broader description is preferred.

Oral drugs commonly undergo hepatic first-pass metabolism, where the drug absorbed from the gut is carried through the portal vein to the liver and metabolized before reaching systemic circulation. This initial metabolism can significantly reduce the amount of active drug that becomes available in the bloodstream, shaping the drug’s bioavailability. The liver, with enzymes like the cytochrome P450 family, converts many medications into more water-soluble forms for elimination, and the extent of this first-pass effect varies by drug. Because of this, some medications have high oral bioavailability only when given in higher oral doses or via nonoral routes to bypass the liver, while others are formulated to resist first-pass metabolism. Thus the statement is true. It’s not accurate to say it never undergoes metabolism or that it bypasses the liver entirely.

The chemical name of a drug is the systematic description of its molecular structure. It specifies which atoms are present and how they are connected, including functional groups and stereochemistry when relevant, giving a precise fingerprint of the molecule itself. For example, a name like 2-acetyloxybenzoic acid encodes the acetyl group attached to benzoic acid, directly reflecting the molecule’s makeup. This is why the chemical name reveals the structure, not how the drug is used, what it looks like, or its therapeutic category. The brand color is just a marketing attribute, the dosing regimen concerns how the drug is taken, and the therapeutic class relates to its mechanism or use rather than its exact structure.